CytomX Therapeutics, Inc. (CTMX)
NASDAQ: CTMX · Real-Time Price · USD
2.040
0.00 (0.00%)
At close: Nov 13, 2026, 4:00 PM EST
2.040
0.00 (0.00%)
Pre-market: Nov 16, 2026, 4:03 AM EST
CytomX Therapeutics Revenue
CytomX Therapeutics had revenue of $1.69M in the quarter ending September 30, 2026, a decrease of -71.69%. This brings the company's total for the last twelve months to $14.03M, down -87.66% year-over-year. In the year 2025, CytomX Therapeutics had annual revenue of $76.20M, down -44.82%. That makes CytomX Therapeutics the 35,781st largest company in the world by revenue and 4,701st in the United States.
Revenue (ttm)
$14.03M
Revenue Growth
-87.66%
P/S Ratio
31.70
Revenue / Employee
$203,304
Employees
69
Market Cap
444.73M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 76.20M | -61.90M | -44.82% |
| Dec 31, 2024 | 138.10M | 36.89M | 36.45% |
| Dec 31, 2023 | 101.21M | 48.05M | 90.38% |
| Dec 31, 2022 | 53.16M | -16.41M | -23.59% |
| Dec 31, 2021 | 69.57M | 1.15M | 1.67% |
| Dec 31, 2020 | 68.43M | 41.53M | 154.36% |
| Dec 31, 2019 | 26.90M | -32.60M | -54.79% |
| Dec 31, 2018 | 59.50M | -12.12M | -16.92% |
| Dec 31, 2017 | 71.62M | 58.78M | 457.59% |
| Dec 31, 2016 | 12.85M | 6.90M | 116.21% |
| Dec 31, 2015 | 5.94M | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | 888.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| MiMedx Group | 303.73M |
| Arvinas | 275.30M |
| Gyre Therapeutics | 110.06M |
| Assembly Biosciences | 67.01M |
| Prothena Corporation | 52.74M |
| Oculis Holding AG | 1.12M |
| Shattuck Labs | 1.00M |
| Avalo Therapeutics | 59.00K |
CTMX News
- 3 days ago - CytomX Therapeutics price target raised to $12 from $11 at JPMorgan - TheFly
- 6 days ago - CytomX Therapeutics Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference - Transcripts
- 9 days ago - CytomX Therapeutics price target raised to $12 from $11 at Wedbush - TheFly
- 10 days ago - CytomX Therapeutics Earnings Call Transcript: Q3 2026 - Transcripts
- 10 days ago - CytomX Therapeutics Quarterly report: Q3 2026 - Filings
- 10 days ago - CytomX Therapeutics Earnings release: Q3 2026 - Filings
- 10 days ago - CytomX Therapeutics reports Q3 EPS (9c), consensus (7c) - TheFly
- 10 days ago - CytomX Therapeutics announces cash runway into 2H of 2028 - TheFly